Zeng Ling-Feng

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China

Dr. Zeng Ling-Feng, Professor, Master’s supervisor & doctoral supervisor, Postdoctoral fellow in Orthopedics, doctor of Medicine, project review expert of National Natural Science Foundation of China, deputy chief editor of “Geriatric Care” (The Planning textbook for Health Service and Management of National Medical Colleges and Universities), editorial board member of 7 national planning textbooks including “Evidence-based Medicine”, “Introduction to Clinical Medicine of Integrated Chinese and Western Medicine”, “Rehabilitation Medicine”, “Introduction to General Practice of Traditional Chinese and Western Medicine”, “Traditional Chinese Medicine Rehabilitation”, “Health Management” and “Medical Records of Traditional Chinese Medicine”; has more than ten years of research experience in orthopedics and metabolomics, bone homeostasis and remodeling, big data analytics, pathogenesis and prevention of osteoporosis and other chronic diseases, medical evidence-based and clinical outcome evaluation. To carry out continuous and in-depth theoretical, clinical and mechanism research around the above main directions, he has close contacted with the clinical departments, combined theory with clinical diagnosis and treatment practice, made full use of the clinical resources of the characteristic and advantageous diseases of traditional Chinese medicine in the specialty of bone injury and joint, and conducted research on the intervention of traditional Chinese medicine in the aspects of disease prevention, evidence-based medicine, material basis and mechanism of action, and translational medicine according to the urgent problems of the specialty diseases and the syndrome characteristics of Lingnan region in China, thus providing scientific basis for the prevention and treatment of orthopedic diseases. At present, he has been selected as master supervisor and doctoral supervisor of Guangzhou University of Chinese Medicine, top-notch talents of Guangdong Provincial Hospital of Chinese Medicine, the third batch of young Chinese medicine truth-seeking scholars, the secretary of collaborative innovation team of disciplines in double first-class high-level universities (Orthopedics of Chinese Medicine) & young and middle-aged subjects and reserve academic leaders of the "double First-class" high-level university establishment collaborative innovation team of TCM bone injury science, the winner of national Excellent Thesis award for PhD students of TCM, outstanding doctoral student of Guangdong Province; the committee member of Expert Committee of "Guangdong, Hong Kong and Macao Youth TCM Inheritance and Innovation Seminar", the committee member of Orthopedic Branch of Chinese Association of Traditional Chinese Medicine, Executive director of Muscle and Bone Maintenance Branch of Chinese Association of Ethnic Medicine, first editor-in-chief of “Self-Prevention and Home Rehabilitation of Osteoporosis (Illustrated Edition)”; Led the development of the program "Osteoporosis Population Risk Assessment and Screening Analysis Platform", optimized the formulation of ten sets of risk assessment and analysis programs for osteosarcoma of different populations by referring to standardized international questionnaire introduction methods; By screening high-risk groups, it can assist in the early diagnosis and treatment of osteosarcoma to provide a basis for disease prevention and treatment. Based on HSP 90's regulation of Hippo-YAP signaling pathway mediating autophagy and affecting BMSCs osteogenic differentiation, the mechanism of kidney-tonifying TCM in prevention and treatment of osteoporosis was further explored. He has hosted 9 projects including National Natural Science Foundation of China, China Postdoctoral Science Foundation, Guangdong Basic and Applied Basic Research Foundation and Programs of Guangdong Provincial Department of Science and Technology. As the first or corresponding author, Dr. Zeng published 87 papers with Scopus H-index 12. He is the chief editor and co-editor of 9 book chapters, and owns 5 patents and 28 computer software Copyrights. 

Ning Zhang

The Chinese University of Hong Kong, Faculty of Medicine, Hong Kong

Dr. Ning Zhang received his PhD degree from The Chinese University of Hong Kong. After finishing his postdoctoral training at Stanford University, Dr. Zhang joined the Faculty of Medicine, The Chinese University of Hong Kong as an Assistant Professor. He has been working in the field of orthopedics, including bone (fracture and defect healing), cartilage (osteoarthritis), and skeletal muscle (sarcopenia) research for more than ten years. He has been well-trained in cellular and molecular biology in vitro techniques and pre-clinical animal in vivo research in orthopedic studies. As an orthopedic researcher, Dr. Zhang’s interests center on cell-based and tissue-engineering therapeutic strategies for immunomodulation during the regeneration of bone and muscle. He is also interested in and has applied novel techniques in pre-clinical and clinical orthopedic studies for detecting differential dynamics and changes during the progress. He is passionate about finding new targets and strategies for the diagnosis and treatment of musculoskeletal disorders.

Mao Zhang

Stanford University, Stanford, CA, USA

Dr. Mao Zhang is a postdoctoral research fellow at Stanford University. Her research interests involve comprehensive understanding of key molecules and pathways that initiate cardiac DNA damage, cell death and inflammation during the development of cardiovascular diseases (CVDs). Her academic training and research experience have provided her with an excellent background in multiple biological disciplines including molecular biology, cell biology, biochemistry, molecular medicine, and bioinformatics. She revealed the splicing landscape of CaMKII-δ in the hearts and elucidated the CaMKII-δ9-UBE2T-DNA damage signaling pathway as a primary mechanism for hypertrophic cardiomyopathy and heart failure. Moreover, she found CaMKII-δ9 was a therapeutic target for cardiac ischemic/reperfusion injury-induced inflammation and related heart diseases. For her postdoctoral research, she uses human induced pluripotent stem cells (hiPSCs) as human-based model system, in conjunction with traditional animal models to investigate key molecules and pathways during the pathogenesis of cardiovascular diseases, especially diseases caused by genetic mutations and environmental stimulation (e.g., smoking, and nutrient overload), thus identifying new drug targets and therapeutic strategies for cardiovascular diseases.